08 June 2023

**You are Invited!**




Approximately 10% of people with cystic fibrosis have rare gene (nonsense) mutations. Within this 10%, there are further breakdowns as to how and why these particular mutations may or may not respond to the currently available CFTR modulators*. As an example, some people with cystic fibrosis may not produce any CFTR protein, meaning CFTR modulators will not work.

Research is being undertaken globally to see how nonsense mutations may be corrected.

In support of raising awareness, Cystic Fibrosis Australia is delighted to welcome three researchers to our upcoming Consumer Connect session, who are currently investigating rare gene mutations within the field of cystic fibrosis - Prof Adam Jaffe, Dr. Shafagh Waters & Prof Peter Wark.

Cystic Fibrosis Australia CEO, Jo Armstrong, will host the session as the panel discuss what rare gene mutations are, how they differ from the 'more common' mutations, why these genes are difficult to treat and diagnose, and what the future holds.

With a panel filled with expertise, this is a great opportunity to submit any questions you have and find out more about Rare Gene Mutations.

*Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators therapies are designed to correct the malfunctioning protein made by the CFTR gene.

**Date**: 22nd June 2023

**Time**: 6.30pm – 7.30pm (AEDT)

**Location**: Online (free to attend)

**To join the session**: Follow this link and log in, or create an account

Rare Gene (nonsense) Mutations | Consumer Connect (padlokt.com)

**Start submitting your questions today**:

Register a question | Consumer Connect (padlokt.com)